Search Results

Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.

One patient developed elevated liver blood tests after receiving Astellas Pharma’s non-hormonal small molecule blocker, leading the regulator to add a warning to the drug’s label.

Vivtex Corporation announces that it has entered a research collaboration with Astellas Pharma Inc. (“Astellas”), a global pharmaceutical company.

Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic research agreement with Astellas Pharma, a global pharmaceutical company with a vision to turn innovative science into value for patients.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

Astellas Pharma US, Inc. (“Astellas”) announced today the company has entered into a sponsored research agreement with the UMass Chan Medical School to proceed with research for an adeno-associated virus (AAV) vector mediated gene therapy for the treatment of Alexander disease, a fatal, ultra-rare disease for which the only current treatment option is supportive care.

Astellas Pharma Inc. announced that it signed a memorandum of understanding with YASKAWA Electric Corporation to begin discussions on the creation of an innovative cell therapy ecosystem through the integration of pharmaceutical and robotics technologies.

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives find themselves faced with policy questions ranging from the Inflation Reduction Act to RFK Jr.

The regulator’s approval on Friday of Vyloy for gastric or gastroesophageal junction cancer makes it the first and only claudin 18.2–targeted therapy approved in the U.S. for these indications, according to Astellas.